You are about to leave the Clinical Value website now.


Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA

Quick Summary

The study aimed to investigate the diagnostic value of serum PIVKA-II levels for early-stage hepatocellular carcinoma (HCC) and the correlation between PIVKA-II levels and hepatitis B virus (HBV) DNA levels. The authors found that elevated serum PIVKA-II levels were significantly associated with early-stage HCC, and that the combination of PIVKA-II and alpha-fetoprotein (AFP) improved the diagnostic accuracy for HCC. They also found a negative correlation between PIVKA-II levels and HBV DNA levels. The authors concluded that serum PIVKA-II levels could be a useful tool than AFP for early detection of HCC in HBV-infected patients.

You May Also Like

13 May 2024

No woman left behind: Increasing access to testing for cervical cancer elimination

Read More
13 May 2024

Advancing women’s health: Project Teal drives cervical cancer screening in Hong Kong

Read More


Be the first to receive updates, event opportunities, and thought leadership insights.